{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:34:18Z","timestamp":1783625658758,"version":"3.55.0"},"reference-count":19,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2018,3,10]]},"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate peripheral blood (PB) for minimal residual disease (MRD) assessment in adults with acute lymphoblastic leukaemia (ALL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed 76 matched bone marrow (BM) aspirate and PB specimens independently for the presence of ALL MRD by six-colour flow cytometry (FC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall rate of BM MRD-positivity was 24% (18\/76) and PB was also MRD-positive in 22% (4\/18) of BM-positive cases. We identified two cases with evidence of leukaemic cells in PB at the time of the extramedullary relapse that were interpreted as MRD-negative in BM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The use of PB MRD as a non-invasive method for monitoring of systemic relapse may have added clinical and diagnostic value in patients with high risk of extramedullary disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jclinpath-2017-204828","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T12:15:31Z","timestamp":1522152931000},"page":"653-658","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease"],"prefix":"10.1136","volume":"71","author":[{"given":"Alissa","family":"Keegan","sequence":"first","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karry","family":"Charest","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Briggs","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"Deangelo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Pozdnyakova","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,3,27]]},"reference":[{"key":"2025121400221386000_71.7.653.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-580027"},{"key":"2025121400221386000_71.7.653.2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2613"},{"key":"2025121400221386000_71.7.653.3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-132837"},{"key":"2025121400221386000_71.7.653.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377713"},{"key":"2025121400221386000_71.7.653.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-185132"},{"key":"2025121400221386000_71.7.653.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2425"},{"key":"2025121400221386000_71.7.653.7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3723186.x"},{"key":"2025121400221386000_71.7.653.8","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.153957"},{"key":"2025121400221386000_71.7.653.9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"2025121400221386000_71.7.653.10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.268"},{"key":"2025121400221386000_71.7.653.11","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/110.1.84"},{"key":"2025121400221386000_71.7.653.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1952"},{"key":"2025121400221386000_71.7.653.13","doi-asserted-by":"publisher","DOI":"10.1309\/7R6MU7R9YWJBY5V4"},{"key":"2025121400221386000_71.7.653.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-726307"},{"key":"2025121400221386000_71.7.653.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1130"},{"key":"2025121400221386000_71.7.653.16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402636"},{"key":"2025121400221386000_71.7.653.17","doi-asserted-by":"publisher","DOI":"10.1038\/nature13317"},{"key":"2025121400221386000_71.7.653.18","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"The Lancet"},{"key":"2025121400221386000_71.7.653.19","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00277-017-3002-1","article-title":"Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid","volume":"96","author":"Sanchez","year":"2017","journal-title":"Ann Hematol"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2017-204828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:22:21Z","timestamp":1765700541000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2017-204828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,27]]},"references-count":19,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7,18]]},"published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1136\/jclinpath-2017-204828"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2017-204828","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,27]]}}}